Valuation: BioNTech SE

Market Cap 20.04B 22.49B 18.38B 16.7B 31.39B 2,125B 32.11B 220B 88.05B 1,125B 84.41B 82.6B 3,563B P/E 2026 *
-13.3x
P/E 2027 * -15.1x
Enterprise Value 8.95B 10.04B 8.2B 7.45B 14.01B 949B 14.33B 98.04B 39.3B 502B 37.68B 36.87B 1,591B EV / Sales 2026 *
5.04x
EV / Sales 2027 * 5.72x
Free-Float
94.76%
Yield 2026 *
-
Yield 2027 * -
1 day+4.35%
1 week+3.08%
Current month+2.87%
1 month-6.40%
3 months-0.71%
6 months-8.71%
Current year-4.73%
1 week 86.44
Extreme 86.44
91.46
1 month 85
Extreme 85
100.02
Current year 79.52
Extreme 79.52
124
1 year 79.52
Extreme 79.52
124
3 years 76.53
Extreme 76.5301
131.49
5 years 76.53
Extreme 76.5301
374.58
10 years 12.52
Extreme 12.525
464
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 59 01/01/2018
Chief Executive Officer 61 02/06/2008
Director of Finance/CFO - 01/07/2025
Director TitleAgeSince
Chairman 56 02/06/2008
Director/Board Member 69 02/06/2008
Director/Board Member 65 01/01/2018
Date Insider Type Main position Quantity % Market Cap. Importance
09/10/26 Sell

Chief Executive Officer

-36,209 0.0150%
07/10/26 Sell

Chief Executive Officer

-24,000 0.0099%
05/10/26 Sell

Chief Executive Officer

-72,000 0.0298%
Change 5-day change 1-year change 3-year change Capi.($)
+4.35%+3.08%-13.48%-5.30% 22.49B
+10.00%+4.50%+58.63%+71.20% 66.87B
+0.98%+4.15%+23.96%+101.39% 56.55B
+1.52%+2.83%+14.35%+79.13% 57.2B
+0.46%-5.47%+25.04%+33.77% 43.47B
+2.82%+5.82%+240.96%+801.17% 42.8B
+6.42%+1.18%+22.18%+105.56% 42.95B
+2.99%-2.90%+100.00%+83.72% 32.11B
+5.32%+5.37%+19.12%+52.98% 34.01B
+5.32%+13.43%-39.82%+342.66% 24.13B
Average +4.02%+2.77%+45.09%+166.63% 42.26B
Weighted average by Cap. +4.10%+2.61%+49.81%+160.81%

Financials

2026 *2027 *
Net sales 1.78B 1.99B 1.63B 1.48B 2.78B 188B 2.84B 19.46B 7.8B 99.64B 7.48B 7.32B 316B 1.8B 2.02B 1.65B 1.5B 2.82B 191B 2.88B 19.72B 7.9B 101B 7.58B 7.41B 320B
Net income -1.49B -1.67B -1.36B -1.24B -2.33B -158B -2.38B -16.3B -6.53B -83.45B -6.26B -6.13B -264B -1.36B -1.53B -1.25B -1.14B -2.14B -145B -2.18B -14.94B -5.99B -76.53B -5.74B -5.62B -242B
Net Debt -11.09B -12.45B -10.17B -9.25B -17.38B -1,176B -17.78B -122B -48.74B -623B -46.73B -45.73B -1,973B -9.76B -10.95B -8.95B -8.13B -15.29B -1,035B -15.63B -107B -42.87B -548B -41.1B -40.22B -1,735B
Projected Income Statement - Annual - BioNTech SE
Logo BioNTech SE
BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The Company is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. It also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.
Employees
7,807
Date Price Change Volume
04/11/26 $90.70 +4.35% 1,352,954
03/11/26 $86.92 -0.70% 1,152,382
02/11/26 $87.53 -0.73% 709,983
30/10/26 $88.17 -1.08% 631,915
29/10/26 $89.13 +1.30% 692,715
Trader
Investor
-
Global
-
Quality
ESG MSCI
-
MarketScreener Ratings - BioNTech SE
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
21
Last Close Price
80.82EUR
Average target price
103.83EUR
Spread / Average Target
+28.47%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - BioNTech SE
  1. Stock Market
  2. Stocks
  3. BNTX Stock